CLYDE_BIOSCIENCES_LIMITED - Accounts


Company Registration No. SC418838 (Scotland)
CLYDE BIOSCIENCES LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2020
PAGES FOR FILING WITH REGISTRAR
CLYDE BIOSCIENCES LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 9
CLYDE BIOSCIENCES LIMITED
BALANCE SHEET
AS AT
31 JULY 2020
31 July 2020
- 1 -
2020
2019
Notes
£
£
£
£
Fixed assets
Intangible assets
3
3,711
4,426
Tangible assets
4
4,050
28,238
Investments
5
1
1
7,762
32,665
Current assets
Debtors
6
52,570
53,077
Cash at bank and in hand
35,542
128,984
88,112
182,061
Creditors: amounts falling due within one year
7
(394,117)
(224,935)
Net current liabilities
(306,005)
(42,874)
Total assets less current liabilities
(298,243)
(10,209)
Creditors: amounts falling due after more than one year
8
(800,000)
(750,000)
Net liabilities
(1,098,243)
(760,209)
Capital and reserves
Called up share capital
9
66
66
Share premium account
1,987,145
1,987,145
Profit and loss reserves
(3,085,454)
(2,747,420)
Total equity
(1,098,243)
(760,209)
CLYDE BIOSCIENCES LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 JULY 2020
31 July 2020
- 2 -

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 July 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 27 April 2021 and are signed on its behalf by:
Mr  R D Henderson
Director
Company Registration No. SC418838
CLYDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2020
- 3 -
1
Accounting policies
Company information

Clyde Biosciences Limited is a private company limited by shares incorporated in Scotland. The registered office is BioCity Scotland, Bo'ness Road, MOTHERWELL, ML1 5UH.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

These financial statements are prepared on the going concern basis. The directors have a reasonable expectation that the company will continue in operational existence for the foreseeable future. However, the directors are aware of certain material uncertainties which may cause doubt on the company's ability to continue as a going concern.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents
10% straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
33% straight line
Computer equipment
50% straight line
CLYDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
1
Accounting policies
(Continued)
- 4 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.8
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

CLYDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
1
Accounting policies
(Continued)
- 5 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

CLYDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
1
Accounting policies
(Continued)
- 6 -
1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Share-based payments

For cash-settled share-based payments, a liability is recognised for the goods and services acquired, measured initially at the fair value of the liability. At the balance sheet date until the liability is settled, and at the date of settlement, the fair value of the liability is remeasured, with any changes in fair value recognised in profit or loss for the year.

1.15
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.16
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.17
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in the profit and loss account for the period.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 6 (2019 - 8).

CLYDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
- 7 -
3
Intangible fixed assets
Other
£
Cost
At 1 August 2019 and 31 July 2020
7,141
Amortisation and impairment
At 1 August 2019
2,715
Amortisation charged for the year
715
At 31 July 2020
3,430
Carrying amount
At 31 July 2020
3,711
At 31 July 2019
4,426
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 August 2019 and 31 July 2020
362,566
Depreciation and impairment
At 1 August 2019
334,328
Depreciation charged in the year
24,188
At 31 July 2020
358,516
Carrying amount
At 31 July 2020
4,050
At 31 July 2019
28,238
5
Fixed asset investments
2020
2019
£
£
Investments
1
1
CLYDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
5
Fixed asset investments
(Continued)
- 8 -
Movements in fixed asset investments
Shares in group undertakings
£
Cost or valuation
At 1 August 2019 & 31 July 2020
1
Carrying amount
At 31 July 2020
1
At 31 July 2019
1
6
Debtors
2020
2019
Amounts falling due within one year:
£
£
Trade debtors
36,244
24,275
Other debtors
16,326
28,802
52,570
53,077
7
Creditors: amounts falling due within one year
2020
2019
£
£
Trade creditors
73,416
19,927
Taxation and social security
17,456
5,173
Other creditors
782
1,100
Accruals and deferred income
302,463
198,735
394,117
224,935
8
Creditors: amounts falling due after more than one year
2020
2019
£
£
Other creditors
800,000
750,000

Other creditors includes a convertible loan. The loan has been secured by floating charges over the company's assets.

CLYDE BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
- 9 -
9
Called up share capital
2020
2019
£
£
Ordinary share capital
Issued and fully paid
660,000 Ordinary Shares of £0.0001 each
66
66
2020-07-312019-08-01false28 April 2021CCH SoftwareCCH Accounts Production 2021.100No description of principal activityProfessor G SmithMr A S DunlopMr A M JohnstonDr P M FinanMr R D HendersonSC4188382019-08-012020-07-31SC4188382020-07-31SC418838core:OtherResidualIntangibleAssets2020-07-31SC418838core:OtherResidualIntangibleAssets2019-07-31SC418838core:IntangibleAssetsOtherThanGoodwill2020-07-31SC418838core:IntangibleAssetsOtherThanGoodwill2019-07-31SC4188382019-07-31SC418838core:OtherPropertyPlantEquipment2020-07-31SC418838core:OtherPropertyPlantEquipment2019-07-31SC418838core:CurrentFinancialInstrumentscore:WithinOneYear2020-07-31SC418838core:CurrentFinancialInstrumentscore:WithinOneYear2019-07-31SC418838core:CurrentFinancialInstruments2020-07-31SC418838core:CurrentFinancialInstruments2019-07-31SC418838core:Non-currentFinancialInstruments2020-07-31SC418838core:Non-currentFinancialInstruments2019-07-31SC418838core:ShareCapital2020-07-31SC418838core:ShareCapital2019-07-31SC418838core:SharePremium2020-07-31SC418838core:SharePremium2019-07-31SC418838core:RetainedEarningsAccumulatedLosses2020-07-31SC418838core:RetainedEarningsAccumulatedLosses2019-07-31SC418838bus:Director82019-08-012020-07-31SC418838core:IntangibleAssetsOtherThanGoodwill2019-08-012020-07-31SC418838core:PlantMachinery2019-08-012020-07-31SC418838core:ComputerEquipment2019-08-012020-07-31SC4188382018-08-012019-07-31SC418838core:IntangibleAssetsOtherThanGoodwill2019-07-31SC418838core:OtherPropertyPlantEquipment2019-07-31SC418838core:OtherPropertyPlantEquipment2019-08-012020-07-31SC418838core:WithinOneYear2020-07-31SC418838core:WithinOneYear2019-07-31SC418838bus:PrivateLimitedCompanyLtd2019-08-012020-07-31SC418838bus:SmallCompaniesRegimeForAccounts2019-08-012020-07-31SC418838bus:FRS1022019-08-012020-07-31SC418838bus:AuditExemptWithAccountantsReport2019-08-012020-07-31SC418838bus:Director12019-08-012020-07-31SC418838bus:Director22019-08-012020-07-31SC418838bus:Director32019-08-012020-07-31SC418838bus:Director42019-08-012020-07-31SC418838bus:Director52019-08-012020-07-31SC418838bus:FullAccounts2019-08-012020-07-31xbrli:purexbrli:sharesiso4217:GBP